SCHEMBL7307116

SCHEMBL7307116

COC(=N)c1ccncc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP1A2 P05177 3/20 0.41
CYP2C19 P33261 3/20 0.41
CYP2C9 P11712 2/20 0.41
NAPRT Q6XQN6 1/20 0.41
TP53 P04637 1/20 0.41
KDM4E B2RXH2 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
MPO P05164 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CYP2A6 P11509 1/20 0.40
HSD17B10 Q99714 2/20 0.39
GAA P10253 2/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
PTGS2 P35354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1821949 0.76 TSHR (0.48) ALDH1A1LMNASMN1; SMN2TDP1KDM4E
SCHEMBL9212489 0.76 LMNA (0.40) ALDH1A1LMNASMN1; SMN2CYP1A2CYP2C19
SCHEMBL11530602 0.76 DGAT1 (0.53) ALDH1A1LMNASMN1; SMN2NAPRTKDM4E
SCHEMBL441069 0.75 TSHR (0.52) ALDH1A1LMNASMN1; SMN2TDP1NAPRT
SCHEMBL6630935 0.75 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2TDP1CYP1A2
SCHEMBL7840555 0.74 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2CYP1A2CYP3A4
Hydrochloric Acid SCHEMBL5442756 0.74 DGAT1 (0.51) ALDH1A1LMNASMN1; SMN2KDM4EHSD17B10
Hydrochloric Acid SCHEMBL647895 0.73 TSHR (0.50) ALDH1A1LMNASMN1; SMN2TDP1KDM4E
SCHEMBL13232308 0.73 TDP1 (0.54) ALDH1A1LMNASMN1; SMN2TDP1KDM4E
SCHEMBL111257 0.73 CA12 (0.54) ALDH1A1LMNASMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289705-A1 PROCESS FOR THE PREPARATION OF RIDINILAZOLE AND CRYSTALLINE FORMS THEREOF SUMMIT (OXFORD) LIMITED (GB) 2022-09-15 US claimed
WO-2022153056-A1 PROCESS FOR PURIFYING RIDINILAZOLE SUMMIT (OXFORD) LIMITED (GB) 2022-07-21 WO claimed
EP-3999502-A1 PROCESS FOR THE PREPARATION OF RIDINILAZOLE AND CRYSTALLINE FORMS THEREOF Summit (Oxford) Limited (GB) 2022-05-25 EP claimed
US-20220289705-A1 PROCESS FOR THE PREPARATION OF RIDINILAZOLE AND CRYSTALLINE FORMS THEREOF SUMMIT (OXFORD) LIMITED (GB) 2022-09-15 US disclosed
WO-2022153056-A1 PROCESS FOR PURIFYING RIDINILAZOLE SUMMIT (OXFORD) LIMITED (GB) 2022-07-21 WO disclosed
EP-3999502-A1 PROCESS FOR THE PREPARATION OF RIDINILAZOLE AND CRYSTALLINE FORMS THEREOF Summit (Oxford) Limited (GB) 2022-05-25 EP disclosed
WO-2020165310-A1 PYRIDINIUM COMPOUNDS AND THEIR USE AS HERBICIDES SYNGENTA CROP PROTECTION AG (CH) 2020-08-20 WO disclosed
WO-2016134854-A1 METHODS FOR THE PREPARATION OF TOPIROXOSTAT AND INTERMEDIATES THEREOF PHARMATHEN S.A. (GR) 2016-09-01 WO disclosed
US-8288423-B2 FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof LEGOCHEM BIOSCIENCE LTD. (KR) 2012-10-16 US disclosed
US-8288423-B2 FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof LEGOCHEM BIOSCIENCE LTD. (KR) 2012-10-16 US disclosed
US-20100184781-A1 FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF LEGOCHEM BIOSCIENCE LTD. (KR) 2010-07-22 US disclosed
US-20100184781-A1 FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF LEGOCHEM BIOSCIENCE LTD. (KR) 2010-07-22 US disclosed
EP-1218360-B1 TRIAZINE KINASE INHIBITORS AMGEN INC (US) 2008-05-28 EP disclosed
US-4788194-A CARDIOTONIC AGENTS, HYPOTENSIVE AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-11-29 US disclosed
US-4716164-A CARDIOTONIC, HYPOTENSIVE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-12-29 US disclosed
US-4558045-A CARDIOTONIC AND HYPOTENSIVE ACTIVITY IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1985-12-10 US disclosed
EP-0154190-A1 Pyridones MERCK PATENT GmbH (DE) 1985-09-11 EP disclosed
US-4489073-A HYPOTENSIVE AND CARDIOTONIC AGENTS IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1984-12-18 US disclosed
EP-0085227-A1 Thiadiazine derivatives, and pharmaceutical compositions containing them IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-08-10 EP disclosed
US-4073780-A INTERMEDIATE FOR A PENICILLANIC ACID PFIZER INC. (US) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184781-A1 FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF F12, F2, TFPI ALDH1A1 4346/4885LMNA 808/4885SMN1; SMN2 4652/4885
US-20220289705-A1 PROCESS FOR THE PREPARATION OF RIDINILAZOLE AND CRYSTALLINE FORMS THEREOF CYP3A4, CYP3A5, CYP3A7 ALDH1A1 269/4885LMNA 1718/4885SMN1; SMN2 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.